FLD

Sigma Introduces 24-70mm F2.8 DG DN II Art Lens; More Info at B&H Photo

Retrieved on: 
Thursday, May 16, 2024
Retail, Consumer Electronics, Technology, Photography, Audio, Video, Specialty, AFL, Autofocus, FLD, Diaphragm, Sigma, Linear actuator, Sony, Travel, Multimedia, B&H, SLD, Telescopic sight

B&H is pleased to share the new Sigma 24-70mm f/2.8 DG DN II Art lens , featuring improved optics, a smaller and lighter design, and faster focusing performance.

Key Points: 
  • B&H is pleased to share the new Sigma 24-70mm f/2.8 DG DN II Art lens , featuring improved optics, a smaller and lighter design, and faster focusing performance.
  • It’s an evolution of one of their most beloved, flagship lenses and a standout zoom within their DG DN Art lineup with enough versatility to handle everyday shooting needs.
  • View the full release here: https://www.businesswire.com/news/home/20240516525384/en/
    Flagship Evolution: Sigma 24-70mm f/2.8 DG DN II Art Lens (Photo: Business Wire)
    Sigma’s reputation for optical excellence doesn’t disappoint, and you can expect to produce well-controlled, sharp, and color-rich imagery in a variety of conditions.
  • Aspherical elements, FLD, and SLD are all present in the optical layout, as well as Nano Porous and Super Multi-Layer Coatings.

Sigma Debuts 15mm F1.4 Ultra-Wide, 500mm F5.6 Super-Tele Prime Lenses - YouTube Introduction Information at B&H

Retrieved on: 
Wednesday, February 21, 2024
Light, Sony, HLA, B&H, Lens, Art, Sport, Element, FLD, SLD, Reproduction, Motion, Environment, Camera

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- B&H is pleased to announce new prime lenses from Sigma's Art and Sports lines for mirrorless cameras: the 15mm f/1.4 DG DN Art and the 500mm f/5.6 DG DN OS Sports lenses. Available in L-mount and Sony E-mount configurations, the pair offers exceptional imaging and professional-grade performance at both ends of the focal-length spectrum.

Key Points: 
  • Sigma expands its Art and Sports lines for mirrorless with a 15mm f/1.4 diagonal fisheye and the handheld-friendly, super-telephoto 500mm f/5.6 lens.
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- B&H is pleased to announce new prime lenses from Sigma's Art and Sports lines for mirrorless cameras : the 15mm f/1.4 DG DN Art and the 500mm f/5.6 DG DN OS Sports lenses.
  • Take a night walk on the wide side with Sigma's latest astro-centric offering, the 15mm f/1.4 DG DN Art lens.
  • Joining two 14mm lenses and a 20mm lens, this bright, ultra-wide prime distinguishes itself as the line's only diagonal fisheye.

Sigma Announces 14mm f/1.4 DG DN Art Lens for Sony E-mount Cameras; YouTube First Look Video and More Info at B&H Photo

Retrieved on: 
Thursday, June 8, 2023
Civilization, Sony FE 28mm F2, SLD, GM, FLD, AFL, Element, HLA, Camera

NEW YORK, June 8, 2023 /PRNewswire/ -- B&H is pleased to share Sigma's announcement of the 14mm f/1.4 DG DN Art lens: a bright, ultra-wide prime engineered for capturing the night sky. Compatible with L and Sony E-mount mirrorless cameras, this ultra-wide, astro-centric lens is equally capable of rendering landscapes and architecture with the exacting clarity that has become synonymous with Sigma's Art line.

Key Points: 
  • Its optical construction incorporates Special Low Dispersion (SLD), "F" Low Dispersion (FLD), and aspherical elements to temper aberrations and distortions including sagittal coma flare, which can distort the shape of stars.
  • Ghosting and flare are also suppressed, thanks to the inclusion of Sigma's Super Multi-Layer Coating.
  • Autofocusing is powered by a high-response linear actuator (HLA) which promises quick and quiet action for stills and video.
  • Matching previous f/1.4 Art lenses, the 14mm features a customizable AFL switch, de-clickable aperture ring, and AF/MF switch.

Echosens Supports American Minority Health Month in April, Highlights Need for Early Liver Disease Detection Among Hispanic Groups

Retrieved on: 
Monday, April 4, 2022
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Medical Devices, Infectious Diseases, Software, Surgery, Hardware, Clinical Trials, Risk, Obesity, Federally Qualified Health Center, Prediabetes, Hispanic and Latino Americans, Central American Minors Program, Liver, Non-alcoholic fatty liver disease, Research, 2009 Davis Cup, Medicaid, CEO, Health, American Diabetes Association, Prevalence, Liver disease, Elastography, Chronic liver disease, NASH, Association, Type 2 diabetes, Health care, NAFLD, Physician, Medicare, Awareness, Fatty liver disease, FLD, Patient, Dietary supplement, Pharmaceutical industry, Diabetes

Fatty liver disease (FLD) is a silent epidemic affecting millions of Americans as the rates of obesity and diabetes continue to accelerate.

Key Points: 
  • Fatty liver disease (FLD) is a silent epidemic affecting millions of Americans as the rates of obesity and diabetes continue to accelerate.
  • Non-alcoholic fatty liver disease (NAFLD) and its more severe from nonalcoholic steatohepatitis (NASH) have a disproportionate impact on minority populations.
  • In comparison to other demographic groups accessing care at Federally Qualified Health Centers (FQHCs), there are increased numbers of young, low-income, uninsured or Medicaid-insured, racial and ethnic minority Americans, says Jon Gingrich, CEO, Echosens North America.
  • During American Minority Health Month, we hope more people will spread the message about the dangers of asymptomatic NAFLD/NASH and the importance of early screenings for liver disease among Hispanic populations.

Cambrex Expands Biopharmaceutical Services Business

Retrieved on: 
Tuesday, March 1, 2022
Therapy, A-DNA, Virus, Hertz, Cambrex Corporation, API, Laboratory, CDMO, FLD, Real-time, Tablet, Mass spectrometry, Multimedia, NGS, Biocatalysis, Substance-related disorder, Organic acid, CGMP, Northern blot, Fine chemical

EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ --Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing biopharmaceutical testing services business.

Key Points: 
  • EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ --Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing biopharmaceutical testing services business.
  • "We are excited to be adding to our fast-growing biopharmaceutical services business," said Cambrex CEO Thomas Loewald.
  • Additionally, Cambrex recently installed a new 600 MHz NMR spectrometer to enhance support for both biopharmaceutical and small molecule programs.
  • Combining these new capabilities with their existing services, Cambrex is now positioned to provide analytical services throughout the lifecycle of small and large molecule therapeutics.

Cambrex Expands Biopharmaceutical Services Business

Retrieved on: 
Tuesday, March 1, 2022
Therapy, A-DNA, Virus, Hertz, Cambrex Corporation, API, Laboratory, CDMO, FLD, Real-time, Tablet, Mass spectrometry, NGS, Biocatalysis, Substance-related disorder, Organic acid, CGMP, Northern blot, Fine chemical

EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ --Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing biopharmaceutical testing services business.

Key Points: 
  • EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ --Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing biopharmaceutical testing services business.
  • "We are excited to be adding to our fast-growing biopharmaceutical services business," said Cambrex CEO Thomas Loewald.
  • Additionally, Cambrex recently installed a new 600 MHz NMR spectrometer to enhance support for both biopharmaceutical and small molecule programs.
  • Combining these new capabilities with their existing services, Cambrex is now positioned to provide analytical services throughout the lifecycle of small and large molecule therapeutics.

Early Identification of Fatty Liver Using Echosens FibroScan Potentially Gives Payers Five-Year Gross Savings of $10+ Million, Confirmed by Independent Study

Retrieved on: 
Monday, December 6, 2021
Technology, Medical Devices, Diabetes, Fitness & Nutrition, Practice Management, Biotechnology, Managed Care, Health, Data Management, Patient, CAP, Ageing, Technology, Medicare, Population, NAFLD, The American Journal of Managed Care, Physician, Cedars-Sinai Medical Center, American Journal, ROI, Obesity, Risk, Elastography, Adult, Medicaid, FLD, Mortality, SBA, Chronic liver disease, Liver, Medical imaging

Published in the American Journal of Managed Care (AJMC), the study results concluded that early identification of patients with FLD through broad placement of VCTE/CAP devices offers cost savings to payers.

Key Points: 
  • Published in the American Journal of Managed Care (AJMC), the study results concluded that early identification of patients with FLD through broad placement of VCTE/CAP devices offers cost savings to payers.
  • Using patented VCTE and CAP, FibroScan is the first totally non-invasive device indicated for use as an aid in the clinical management of patients with liver disease.
  • The studys model was built to project medical cost savings driven by the device, relative to the net cost of the device.
  • FibroScan is supported by over 3,000 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

Echosens Presents Research at 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan Mitigates Risk of Patients Developing Fibrosis/Cirrhosis

Retrieved on: 
Thursday, November 11, 2021
Biotechnology, Practice Management, Technology, Other Health, Diabetes, Health, General Health, Other Technology, Medical Devices, Hospitals, Clinical Trials, Population, Fatty liver disease, American Association, Type 2 diabetes, Pioneer, Cirrhosis, CEO, Elastography, Comorbidity, Technology, Liver disease, Liver, AASLD, Institute of Liver and Biliary Sciences, NAFLD, Association, NASH, Solution, Publication, FLD, CAP, Fibrosis, American Association for the Study of Liver Diseases, Diabetes, Patient, Risk, Obesity, Dietary supplement, Medical imaging, Pharmaceutical industry

Our technology solutions serve as the cornerstone of non-invasive tests for the future of liver disease managementacross the liver care continuum and all population groups.

Key Points: 
  • Our technology solutions serve as the cornerstone of non-invasive tests for the future of liver disease managementacross the liver care continuum and all population groups.
  • The expanding body of data supports FibroScan as an early assessment and monitoring tool that can mitigate the risk that patients will develop more serious conditions like fibrosis, cirrhosis and liver cancer.
  • Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan, the non-invasive solution for comprehensive management of liver health.
  • Echosens has made FibroScan available in over 100+ countries enabling millions of liver examinations worldwide.

OneConnect Announces Partnership with Indonesia-based Bank Mayapada, to Enable Digital Onboarding through a Comprehensive Suite of Innovative Solutions

Retrieved on: 
Friday, November 5, 2021
Cloud, Compliance, Efficiency, COVID-19, Data lake, Industry, Ping An Insurance, Strategic planning, Government, CEO, Go to market, Technology, New, TBK, Artificial intelligence, Research, Machine learning, IDX, OMG, Partnership, Bank, Risk management, Company, PT, Macquarie, The Company, Solution, FLD, NYSE, Financial Services Authority (Indonesia), Patent, Cryptocurrency

one of Indonesia's largest private banks with more than 216 offices and branch offices across Indonesia, to enable digitisation of banking services through a comprehensive suite of technological solutions developed by OneConnect.

Key Points: 
  • one of Indonesia's largest private banks with more than 216 offices and branch offices across Indonesia, to enable digitisation of banking services through a comprehensive suite of technological solutions developed by OneConnect.
  • This partnership will see OneConnect provide Bank Mayapada with electronic know-your-customer (eKYC) technology, augmented with artificial intelligence (AI) technology to validate the authenticity of customers' indentities.
  • Bank Mayapada Internasional, Tbk., said "We are pleased to strengthen Bank Mayapada's digital journey with next gen technologies together with OneConnect."
  • These solutions enable our customers' digital transformations, which seek to increase revenue, manage risks, improve efficiency, enhance service quality and reduce costs.